


Supplementary Materials for
Consolidated Financial Statements for
the Fiscal Year 2024.12 (IFRS)



CHUGAI PHARMACEUTICAL

 A member of the Roche group

- Notes: 1. Portions of this report that refer to performance forecasts or any other future events are believed to be reasonable under information available at the time of the forecasts. Actual results may materially differ from these forecasts due to changes in circumstances.
2. Amounts shown in this report are rounded to the nearest 0.1 billion yen. Variance and % are calculated based on the amounts shown.
3. Exchange rates used for each period are as follows.

Weighted average rate*

(Yen)

	Actual FY2023				Actual FY2024				Assumption FY2025
	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	1-12
	YTD	YTD	YTD	Full-year	YTD	YTD	YTD	Full-year	Full-year
CHF	137.05	138.30	138.62	140.31	162.70	160.90	160.43	161.02	171.00
EUR	141.96	141.96	149.03	151.38	161.10	164.63	163.89	163.30	160.00
USD	132.79	133.45	133.42	134.21	131.49	135.45	136.39	139.11	148.00
SGD	99.24	99.39	101.74	103.75	110.08	112.60	114.77	113.60	113.00

*Weighted average of the exchange rates used to record foreign currency transactions included in categories from revenue to operating profit

Market average rate

	Actual FY2023				Actual FY2024			
	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12
	YTD	YTD	YTD	Full-year	YTD	YTD	YTD	Full-year
CHF	143.05	147.78	152.93	156.31	169.79	171.06	171.46	172.00
EUR	141.99	145.68	149.52	151.91	161.11	164.43	164.26	163.81
USD	132.35	134.79	138.03	140.49	148.35	152.06	151.12	151.42
SGD	99.32	100.90	102.98	104.62	110.71	112.92	112.96	113.31

Period-end rate

	Actual FY2023				Actual FY2024			
	31 Mar.	30 Jun.	30 Sep.	31 Dec.	31 Mar.	30 Jun.	30 Sep.	31 Dec.
CHF	145.27	160.96	163.06	167.49	167.93	178.94	169.13	173.50
EUR	144.63	157.31	157.65	156.45	163.33	172.12	158.72	163.08
USD	132.66	144.78	149.24	141.38	151.39	160.83	142.18	156.83
SGD	99.92	106.73	109.25	107.09	112.12	118.41	111.05	115.27

Reconciliation of IFRS results to Core results

(Billions of yen)

	FY2023				FY2024			
	1–12				1–12			
	IFRS results	Intangible assets	Others	Core results	IFRS results	Intangible assets	Others	Core results
Revenue	1,111.4	–	–	1,111.4	1,170.6	–	–	1,170.6
Sales	974.5	–	–	974.5	997.9	–	–	997.9
Other revenue	136.9	–	–	136.9	172.7	–	–	172.7
Cost of sales	(413.3)	1.2	0.1	(412.0)	(339.4)	1.3	–	(338.1)
Gross profit	698.1	1.2	0.1	699.4	831.2	1.3	–	832.5
Research and development	(174.9)	5.4	6.7	(162.8)	(181.4)	4.4	0.1	(176.9)
Selling, general and administration	(112.6)	–	10.6	(102.0)	(110.1)	–	7.9	(102.2)
Other operating income (expense)	28.6	–	(12.5)	16.1	2.3	–	0.4	2.7
Operating profit	439.2	6.6	4.9	450.7	542.0	5.7	8.4	556.1
Financing costs	(0.0)	–	–	(0.0)	0.0	–	–	0.0
Other financial income (expense)	4.7	–	–	4.7	1.0	–	–	1.0
Profit before taxes	443.8	6.6	4.9	455.3	543.0	5.7	8.4	557.1
Income taxes	(118.3)	(2.0)	(1.4)	(121.8)	(155.7)	(1.7)	(2.6)	(160.0)
Net income	325.5	4.6	3.5	333.6	387.3	4.0	5.8	397.1
Attributable to	325.5	4.6	3.5	333.6	387.3	4.0	5.8	397.1
Chugai shareholders	325.5	4.6	3.5	333.6	387.3	4.0	5.8	397.1
Non-controlling interests	–	–	–	–	–	–	–	–

Core results

Chugai discloses its results on a Core basis from 2013 in conjunction with its transition to IFRS. Core results are the results after adjusting non-recurring items recognized by Chugai to IFRS results. Chugai's recognition of non-recurring items may differ from that of Roche due to the difference in the scale of operations, the scope of business and other factors. Core results are used by Chugai as an internal performance indicator, for explaining the status of recurring profits both internally and externally, and as the basis for payment-by-results.

The table above shows the reconciliation of IFRS results into Core results. The detail is as below.

Intangible assets

Amortization (1.6 billion yen in 2023 and 1.6 billion yen in 2024)

Impairment (5.1 billion yen in 2023 and 4.1 billion in 2024)

Others

Early Retirement Incentive Program (10.3 billion yen in 2023 and None in 2024)

Business rebuilding expenses (None in 2023 and 7.9 billion yen in 2024)

Restructuring expenses, etc. including gain on disposal of assets. (–5.5 billion yen in 2023 and 0.5 billion yen in 2024)

IFRS results (QTR)

(Billions of yen)

	Actual FY2023				Actual FY2024							
	1-3	4-6	7-9	10-12	1-3	Change	4-6	Change	7-9	Change	10-12	Change
	QTR	QTR	QTR	QTR	QTR	(%)	QTR	(%)	QTR	(%)	QTR	(%)
Revenue	312.2	267.4	257.9	273.8	236.9	(24.1)	315.9	+18.1	315.7	+22.4	302.1	+10.3
Sales	291.5	231.5	219.0	232.4	204.5	(29.8)	281.1	+21.4	264.8	+20.9	247.6	+6.5
Domestic	192.7	120.9	115.6	128.8	103.2	(46.4)	114.0	(5.7)	114.5	(1.0)	129.5	+0.5
Overseas	98.8	110.6	103.4	103.6	101.3	+2.5	167.1	+51.1	150.3	+45.4	118.1	+14.0
Other revenue	20.7	35.9	38.9	41.4	32.5	+57.0	34.9	(2.8)	50.9	+30.8	54.5	+31.6
Royalty income and profit-sharing income	20.7	28.6	38.4	39.8	21.0	+1.4	33.8	+18.2	39.6	+3.1	53.0	+33.2
Other operating income	0.0	7.3	0.5	1.6	11.5	-	1.0	(86.3)	11.2	22times	1.5	(6.3)
Cost of sales	(151.3)	(91.7)	(78.3)	(92.1)	(72.9)	(51.8)	(87.9)	(4.1)	(84.2)	+7.5	(94.3)	+2.4
(% of Sales)	51.9	39.6	35.8	39.6	35.6	-	31.3	-	31.8	-	38.1	-
Gross profit	160.9	175.8	179.6	181.8	164.0	+1.9	228.0	+29.7	231.5	+28.9	207.8	+14.3
(% of Revenue)	51.5	65.7	69.6	66.4	69.2	-	72.2	-	73.3	-	68.8	-
Research and development	(42.9)	(44.6)	(45.6)	(41.9)	(41.4)	(3.5)	(42.9)	(3.8)	(44.9)	(1.5)	(52.2)	+24.6
(% of Revenue)	13.7	16.7	17.7	15.3	17.5	-	13.6	-	14.2	-	17.3	-
Selling, general and administration	(21.0)	(33.3)	(27.5)	(30.8)	(22.6)	+7.6	(27.3)	(18.0)	(27.8)	+1.1	(32.4)	+5.2
(% of Revenue)	6.7	12.5	10.7	11.2	9.5	-	8.6	-	8.8	-	10.7	-
Other operating income (expense)	1.3	14.7	0.2	12.4	(0.2)	-	0.6	(95.9)	1.6	+700.0	0.3	(97.6)
Operating profit	98.3	112.6	106.7	121.6	99.9	+1.6	158.3	+40.6	160.4	+50.3	123.4	+1.5
(% of Revenue)	31.5	42.1	41.4	44.4	42.2	-	50.1	-	50.8	-	40.8	-
Financing costs	(0.0)	(0.0)	(0.0)	(0.0)	0.0	-	0.0	-	-	-	(0.0)	0.0
Other financial income (expense)	1.4	1.4	0.8	1.1	0.0	-	0.5	(64.3)	(1.6)	-	2.1	+90.9
Profit before taxes	99.7	114.0	107.5	122.7	99.9	+0.2	158.8	+39.3	158.8	+47.7	125.5	+2.3
(% of Revenue)	31.9	42.6	41.7	44.8	42.2	-	50.3	-	50.3	-	41.5	-
Income taxes	(26.2)	(30.8)	(29.9)	(31.5)	(25.5)	(2.7)	(46.9)	+52.3	(49.3)	+64.9	(33.9)	+7.6
Net income	73.5	83.2	77.6	91.2	74.4	+1.2	111.9	+34.5	109.5	+41.1	91.6	+0.4
(% of Revenue)	23.5	31.1	30.1	33.3	31.4	-	35.4	-	34.7	-	30.3	-
Attributable to												
Chugai shareholders	73.5	83.2	77.6	91.2	74.4	+1.2	111.9	+34.5	109.5	+41.1	91.6	+0.4
Non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	-
Earnings per share												
Basic (yen)	44.68	50.57	47.15	55.43	45.22	+1.2	67.98	+34.4	66.54	+41.1	55.64	+0.4
Diluted (yen)	44.67	50.56	47.14	55.43	45.21	+1.2	67.97	+34.4	66.54	+41.2	55.64	+0.4

Other financial income (expense) includes net amount of FX related gains/losses.

IFRS results (YTD)

(Billions of yen)

	Actual				Actual							
	FY2023				FY2024							
	1-3 YTD	1-6 YTD	1-9 YTD	1-12 YTD	1-3 YTD	Change (%)	1-6 YTD	Change (%)	1-9 YTD	Change (%)	1-12 YTD	Change (%)
Revenue	312.2	579.7	837.6	1,111.4	236.9	(24.1)	552.9	(4.6)	868.5	+3.7	1,170.6	+5.3
Sales	291.5	523.0	742.1	974.5	204.5	(29.8)	485.5	(7.2)	750.3	+1.1	997.9	+2.4
Domestic	192.7	313.6	429.2	558.0	103.2	(46.4)	217.2	(30.7)	331.7	(22.7)	461.1	(17.4)
Overseas	98.8	209.4	312.9	416.5	101.3	+2.5	268.4	+28.2	418.7	+33.8	536.8	+28.9
Other revenue	20.7	56.6	95.5	136.9	32.5	+57.0	67.3	+18.9	118.2	+23.8	172.7	+26.2
Royalty income and profit-sharing income	20.7	49.3	87.7	127.5	21.0	+1.4	54.8	+11.2	94.5	+7.8	147.4	+15.6
Other operating income	0.0	7.3	7.8	9.4	11.5	–	12.5	+71.2	23.8	+205.1	25.3	+169.1
Cost of sales	(151.3)	(243.0)	(321.2)	(413.3)	(72.9)	(51.8)	(160.9)	(33.8)	(245.1)	(23.7)	(339.4)	(17.9)
(% of Sales)	51.9	46.5	43.3	42.4	35.6	–	33.1	–	32.7	–	34.0	–
Gross profit	160.9	336.7	516.3	698.1	164.0	+1.9	392.0	+16.4	623.4	+20.7	831.2	+19.1
(% of Revenue)	51.5	58.1	61.6	62.8	69.2	–	70.9	–	71.8	–	71.0	–
Research and development	(42.9)	(87.4)	(133.0)	(174.9)	(41.4)	(3.5)	(84.3)	(3.5)	(129.2)	(2.9)	(181.4)	+3.7
(% of Revenue)	13.7	15.1	15.9	15.7	17.5	–	15.2	–	14.9	–	15.5	–
Selling, general and administration	(21.0)	(54.3)	(81.8)	(112.6)	(22.6)	+7.6	(49.9)	(8.1)	(77.7)	(5.0)	(110.1)	(2.2)
(% of Revenue)	6.7	9.4	9.8	10.1	9.5	–	9.0	–	8.9	–	9.4	–
Other operating income (expense)	1.3	16.0	16.1	28.6	(0.2)	–	0.4	(97.5)	2.1	(87.0)	2.3	(92.0)
Operating profit	98.3	210.9	317.6	439.2	99.9	+1.6	258.2	+22.4	418.6	+31.8	542.0	+23.4
(% of Revenue)	31.5	36.4	37.9	39.5	42.2	–	46.7	–	48.2	–	46.3	–
Financing costs	(0.0)	(0.0)	(0.0)	(0.0)	0.0	–	0.0	–	0.0	–	0.0	–
Other financial income (expense)	1.4	2.8	3.6	4.7	0.0	–	0.5	(82.1)	(1.1)	–	1.0	(78.7)
Profit before taxes	99.7	213.7	321.1	443.8	99.9	+0.2	258.7	+21.1	417.5	+30.0	543.0	+22.4
(% of Revenue)	31.9	36.9	38.3	39.9	42.2	–	46.8	–	48.1	–	46.4	–
Income taxes	(26.2)	(57.0)	(86.9)	(118.3)	(25.5)	(2.7)	(72.4)	+27.0	(121.8)	+40.2	(155.7)	+31.6
Net income	73.5	156.7	234.3	325.5	74.4	+1.2	186.3	+18.9	295.8	+26.2	387.3	+19.0
(% of Revenue)	23.5	27.0	28.0	29.3	31.4	–	33.7	–	34.1	–	33.1	–
Attributable to												
Chugai shareholders	73.5	156.7	234.3	325.5	74.4	+1.2	186.3	+18.9	295.8	+26.2	387.3	+19.0
Non-controlling interests	–	–	–	–	–	–	–	–	–	–	–	–
Earnings per share												
Basic (yen)	44.68	95.25	142.40	197.83	45.22	+1.2	113.20	+18.8	179.75	+26.2	235.39	+19.0
Diluted (yen)	44.67	95.23	142.37	197.80	45.21	+1.2	113.19	+18.9	179.72	+26.2	235.36	+19.0

Other financial income (expense) includes net amount of FX related gains/losses.

Core results (QTR)

(Billions of yen)

	Actual FY2023				Actual FY2024							
	1-3	4-6	7-9	10-12	1-3	Change (%)	4-6	Change (%)	7-9	Change (%)	10-12	Change (%)
	QTR	QTR	QTR	QTR	QTR		QTR		QTR		QTR	
Revenue	312.2	267.4	257.9	273.8	236.9	(24.1)	315.9	+18.1	315.7	+22.4	302.1	+10.3
Sales	291.5	231.5	219.0	232.4	204.5	(29.8)	281.1	+21.4	264.8	+20.9	247.6	+6.5
Domestic	192.7	120.9	115.6	128.8	103.2	(46.4)	114.0	(5.7)	114.5	(1.0)	129.5	+0.5
Overseas	98.8	110.6	103.4	103.6	101.3	+2.5	167.1	+51.1	150.3	+45.4	118.1	+14.0
Other revenue	20.7	35.9	38.9	41.4	32.5	+57.0	34.9	(2.8)	50.9	+30.8	54.5	+31.6
Royalty income and profit-sharing income	20.7	28.6	38.4	39.8	21.0	+1.4	33.8	+18.2	39.6	+3.1	53.0	+33.2
Other operating income	0.0	7.3	0.5	1.6	11.5	–	1.0	(86.3)	11.2	22times	1.5	(6.3)
Cost of sales	(151.0)	(91.3)	(78.0)	(91.7)	(72.6)	(51.9)	(87.6)	(4.1)	(83.9)	+7.6	(94.0)	+2.5
(% of Sales)	51.8	39.4	35.6	39.5	35.5	–	31.2	–	31.7	–	38.0	–
Gross profit	161.2	176.2	179.9	182.1	164.3	+1.9	228.3	+29.6	231.8	+28.8	208.1	+14.3
(% of Revenue)	51.6	65.9	69.8	66.5	69.4	–	72.3	–	73.4	–	68.9	–
Research and development	(36.1)	(40.4)	(45.1)	(41.1)	(41.2)	+14.1	(42.8)	+5.9	(43.9)	(2.7)	(49.1)	+19.5
(% of Revenue)	11.6	15.1	17.5	15.0	17.4	–	13.5	–	13.9	–	16.3	–
Selling, general and administration	(21.0)	(24.0)	(26.4)	(30.5)	(21.2)	+1.0	(25.4)	+5.8	(25.9)	(1.9)	(29.8)	–2.3
(% of Revenue)	6.7	9.0	10.2	11.1	8.9	–	8.0	–	8.2	–	9.9	–
Other operating income (expense)	1.3	14.9	0.2	(0.3)	0.2	(84.6)	0.6	(96.0)	1.6	+700.0	0.3	–
Operating profit	105.4	126.6	108.6	110.1	102.1	(3.1)	160.7	+26.9	163.7	+50.7	129.5	+17.6
(% of Revenue)	33.8	47.3	42.1	40.2	43.1	–	50.9	–	51.9	–	42.9	–
Financing costs	(0.0)	(0.0)	(0.0)	(0.0)	0.0	–	0.0	–	0.0	–	(0.0)	0.0
Other financial income (expense)	1.4	1.4	0.8	1.1	0.0	–	0.5	(64.3)	(1.6)	–	2.1	+90.9
Profit before taxes	106.7	128.0	109.3	111.3	102.1	(4.3)	161.2	+25.9	162.1	+48.3	131.6	+18.2
(% of Revenue)	34.2	47.9	42.4	40.7	43.1	–	51.0	–	51.3	–	43.6	–
Income taxes	(28.3)	(35.0)	(30.5)	(28.0)	(26.2)	(7.4)	(47.7)	+36.3	(50.3)	+64.9	(35.8)	+27.9
Net income	78.4	93.0	78.9	83.3	76.0	(3.1)	113.5	+22.0	111.8	+41.7	95.8	+15.0
(% of Revenue)	25.1	34.8	30.6	30.4	32.1	–	35.9	–	35.4	–	31.7	–
Attributable to												
Chugai shareholders	78.4	93.0	78.9	83.3	76.0	(3.1)	113.5	+22.0	111.8	+41.7	95.8	+15.0
Non-controlling interests	–	–	–	–	–	–	–	–	–	–	–	–
Core earnings per share (diluted) (yen)	47.66	56.53	47.92	50.59	46.16	(3.1)	68.99	+22.0	67.93	+41.8	58.22	+15.1

Please see page 1 “Reconciliation of IFRS results to Core results” for the detail of the adjustments.

Core earnings per share (diluted) (yen) : Net income attributable to Chugai shareholders / Weighted average number of shares in issue used to calculate diluted earnings per share.

Other financial income (expense) includes net amount of FX related gains/losses.

Core results (YTD)

(Billions of yen)

	Actual				Actual								Forecast (Jan 30th announced)	
	FY2023				FY2024								FY2025	
	1-3	1-6	1-9	1-12	1-3	Change (%)	1-6	Change (%)	1-9	Change (%)	1-12	Change (%)	1-12	Change (%)
	YTD	YTD	YTD	YTD	YTD		YTD		YTD		YTD		YTD	
Revenue	312.2	579.7	837.6	1,111.4	236.9	(24.1)	552.9	(4.6)	868.5	+3.7	1170.6	+5.3	1,190.0	+1.7
Sales	291.5	523.0	742.1	974.5	204.5	(29.8)	485.5	(7.2)	750.3	+1.1	997.9	+2.4	1,018.0	+2.0
Domestic	192.7	313.6	429.2	558.0	103.2	(46.4)	217.2	(30.7)	331.7	(22.7)	461.1	(17.4)	462.5	+0.3
Overseas	98.8	209.4	312.9	416.5	101.3	+2.5	268.4	+28.2	418.7	+33.8	536.8	+28.9	555.5	+3.5
Other revenue	20.7	56.6	95.5	136.9	32.5	+57.0	67.3	+18.9	118.2	+23.8	172.7	+26.2	172.0	(0.4)
Royalty income and profit-sharing income	20.7	49.3	87.7	127.5	21.0	+1.4	54.8	+11.2	94.5	+7.8	147.4	+15.6	165.7	+12.4
Other operating income	0.0	7.3	7.8	9.4	11.5	–	12.5	+71.2	23.8	+205.1	25.3	+169.1	6.3	(75.1)
Cost of sales	(151.0)	(242.3)	(320.2)	(412.0)	(72.6)	(51.9)	(160.2)	(33.9)	(244.1)	(23.8)	(338.1)	(17.9)	(341.0)	+0.9
(% of Sales)	51.8	46.3	43.1	42.3	35.5	–	33.0	–	32.5	–	33.9	–	33.5	–
Gross profit	161.2	337.4	517.3	699.4	164.3	+1.9	392.6	+16.4	624.4	+20.7	832.5	+19.0	849.0	+2.0
(% of Revenue)	51.6	58.2	61.8	62.9	69.4	–	71.0	–	71.9	–	71.1	–	71.3	–
Research and development	(36.1)	(76.5)	(121.7)	(162.8)	(41.2)	+14.1	(84.0)	+9.8	(127.9)	+5.1	(176.9)	+8.7	(178.0)	+0.6
(% of Revenue)	11.6	13.2	14.5	14.6	17.4	–	15.2	–	14.7	–	15.1	–	15.0	–
Selling, general and administration	(21.0)	(45.0)	(71.4)	(102.0)	(21.2)	+1.0	(46.6)	+3.6	(72.5)	+1.5	(102.2)	+0.2	(101.0)	–1.2
(% of Revenue)	6.7	7.8	8.5	9.2	8.9	–	8.4	–	8.3	–	8.7	–	8.5	–
Other operating income (expense)	1.3	16.2	16.3	16.1	0.2	(84.6)	0.8	(95.1)	2.4	(85.3)	2.7	(83.2)	–	–
Operating profit	105.4	232.0	340.5	450.7	102.1	(3.1)	262.8	+13.3	426.6	+25.3	556.1	+23.4	570.0	+2.5
(% of Revenue)	33.8	40.0	40.7	40.6	43.1	–	47.5	–	49.1	–	47.5	–	47.9	–
Financing costs	(0.0)	(0.0)	(0.0)	(0.0)	0.0	–	0.0	–	0.0	–	0.0	–		
Other financial income (expense)	1.4	2.8	3.6	4.7	0.0	–	0.5	(82.1)	(1.1)	–	1.0	(78.7)		
Profit before taxes	106.7	234.7	344.1	455.3	102.1	(4.3)	263.3	+12.2	425.5	+23.7	557.1	+22.4		
(% of Revenue)	34.2	40.5	41.1	41.0	43.1	–	47.6	–	49.0	–	47.6	–		
Income taxes	(28.3)	(63.3)	(93.8)	(121.8)	(26.2)	(7.4)	(73.8)	+16.6	(124.2)	+32.4	(160.0)	+31.4		
Net income	78.4	171.4	250.3	333.6	76.0	(3.1)	189.5	+10.6	301.3	+20.4	397.1	+19.0	410.0	+3.2
(% of Revenue)	25.1	29.6	29.9	30.0	32.1	–	34.3	–	34.7	–	33.9	–	34.5	–
Attributable to														
Chugai shareholders	78.4	171.4	250.3	333.6	76.0	(3.1)	189.5	+10.6	301.3	+20.4	397.1	+19.0		
Non-controlling interests	–	–	–	–	–	–	–	–	–	–	–	–		
Weighted average number of shares in issue used to calculate diluted earnings per share (Millions of shares)	1,645	1,645	1,645	1,645	1,646	0.1	1,646	0.1	1,646	0.1	1,646	0.1		
Core earnings per share (diluted) (yen)	47.66	104.19	152.11	202.71	46.16	(3.1)	115.15	+10.5	183.09	+20.4	241.31	+19.0	250.00	+3.6
Core payout ratio (%)				39.5								40.6	100.0	–
Dividend per share (Full year) (yen)				80								98	250	–
Dividend per share (Year end) (yen)				40								57	125	–
Dividend per share (Half year) (yen)				40								41	125	–

Please see page 1 “Reconciliation of IFRS results to Core results” for the detail of the adjustments.

Core earnings per share (diluted) (yen) : Net income attributable to Chugai shareholders / Weighted average number of shares in issue used to calculate diluted earnings per share.

Other financial income (expense) includes net amount of FX related gains/losses.

The dividend forecast for the full year is an annual total of 250 yen per share, which includes an ordinary dividend of 100 yen (50 yen interim, 50 yen year-end) and a 100th anniversary dividend of 150 yen (75 yen interim, 75 yen year-end).

Core statements of revenue (QTR)

(Billions of yen)

	Actual				Actual									
	FY2023				FY2024									
	1-3	4-6	7-9	10-12	1-3	Change	4-6	Change	7-9	Change	10-12	Change		
	QTR	QTR	QTR	QTR	QTR	(%)	QTR	(%)	QTR	(%)	QTR	(%)		
Sales	291.5	231.5	219.0	232.4	204.5	(29.8)	281.1	+21.4	264.8	+20.9	247.6	+6.5		
Domestic	192.7	120.9	115.6	128.8	103.2	(46.4)	114.0	(5.7)	114.5	(1.0)	129.5	+0.5		
Oncology	60.0	66.6	64.8	68.8	56.1	(6.5)	62.6	(6.0)	61.6	(4.9)	67.4	(2.0)		
Tecentriq	15.1	16.6	16.3	17.6	14.5	(4.0)	16.6	0.0	16.3	0.0	18.0	+2.3		
Avastin	13.0	13.2	12.1	11.5	8.7	(33.1)	8.7	(34.1)	8.2	(32.2)	8.2	(28.7)		
Polivy	7.2	8.7	9.6	10.0	7.4	+2.8	8.3	(4.6)	8.8	(8.3)	9.7	(3.0)		
Alecensa	6.6	8.0	7.5	8.2	6.6	0.0	8.2	+2.5	7.5	0.0	8.6	+4.9		
Phesgo	–	–	–	0.7	3.2	–	5.4	–	6.5	–	8.4	12times		
Perjeta	7.5	8.6	8.5	9.0	6.1	(18.7)	5.2	(39.5)	4.4	(48.2)	4.3	(52.2)		
Kadcyla	3.8	3.9	4.0	4.3	3.6	(5.3)	4.3	+10.3	4.3	+7.5	4.7	+9.3		
Herceptin	1.3	1.2	1.1	1.1	0.7	(46.2)	0.6	(50.0)	0.5	(54.5)	0.5	(54.5)		
Foundation Medicine	1.9	1.8	1.9	1.8	1.8	(5.3)	1.8	0.0	2.2	15.8	1.9	+5.6		
Other products	3.6	4.6	3.9	4.6	3.4	(5.6)	3.5	(23.9)	3.0	(23.1)	3.1	(32.6)		
Specialty	132.7	54.4	50.8	60.0	47.0	(64.6)	51.3	(5.7)	52.9	+4.1	62.1	+3.5		
Hemlibra	12.4	14.4	13.8	14.3	12.5	+0.8	14.9	+3.5	14.1	+2.2	17.5	+22.4		
Actemra	9.9	11.2	11.1	12.0	10.2	+3.0	12.2	+8.9	12.4	+11.7	13.1	+9.2		
Enspryng	4.7	6.2	6.0	7.1	5.8	+23.4	5.8	(6.5)	6.2	+3.3	6.9	(2.8)		
Vabysmo	3.0	3.8	4.0	4.6	4.0	+33.3	5.2	+36.8	5.6	+40.0	6.7	+45.7		
Evrysdi	3.0	3.5	3.7	4.2	3.4	+13.3	4.1	+17.1	3.8	+2.7	4.6	+9.5		
Mircerca	2.0	2.1	2.1	2.2	1.5	(25.0)	1.7	(19.0)	1.6	(23.8)	1.7	(22.7)		
CellCept	1.6	1.8	1.7	1.9	1.5	(6.3)	1.6	(11.1)	1.6	(5.9)	2.1	+10.5		
Edirol	1.8	2.0	1.8	1.9	1.4	(22.2)	1.5	(25.0)	1.3	(27.8)	0.8	(57.9)		
Piasky	–	–	–	–	–	–	0.4	–	0.9	–	1.3	–		
Ronapreve	81.2	–	–	–	–	–	–	–	–	–	–	–		
Other products	13.1	9.4	6.6	11.9	6.7	(48.9)	4.0	(57.4)	5.5	(16.7)	7.3	(38.7)		
Tamiful	5.3	0.1	0.7	3.7	1.3	(75.5)	0.1	0.0	0.6	(14.3)	2.6	(29.7)		
Overseas	98.8	110.6	103.4	103.6	101.3	+2.5	167.1	+51.1	150.3	+45.4	118.1	+14.0		
Hemlibra	46.0	58.0	67.9	40.5	57.8	+25.7	102.8	+77.2	92.9	+36.8	54.2	+33.8		
To Roche	45.2	57.1	67.1	39.4	56.9	+25.9	101.9	+78.5	91.7	+36.7	52.9	+34.3		
Actemra	31.8	33.3	21.5	41.0	23.4	(26.4)	38.2	+14.7	32.0	+48.8	38.3	(6.6)		
To Roche	30.7	32.3	20.3	40.0	22.1	(28.0)	37.0	+14.6	30.7	+51.2	37.0	(7.5)		
Alecensa	16.7	14.7	6.5	17.8	14.0	(16.2)	16.5	+12.2	16.1	+147.7	16.1	(9.6)		
To Roche	16.0	14.1	5.8	16.9	13.2	(17.5)	15.8	+12.1	15.4	+165.5	15.4	(8.9)		
Enspryng	0.7	0.4	3.2	(0.1)	2.1	+200.0	2.9	+625.0	3.7	15.6	5.0	–		
To Roche	0.7	0.4	3.2	(0.1)	2.1	+200.0	2.9	+625.0	3.6	12.5	4.9	–		
Sigmart	1.7	2.1	2.1	2.2	1.7	0.0	2.5	+19.0	1.9	–9.5	1.9	(13.6)		
Neutrogen	1.9	2.0	2.1	2.1	2.1	+10.5	2.5	+25.0	2.1	0.0	1.9	(9.5)		
Edirol	0.0	0.0	0.0	0.0	0.1	–	0.1	–	0.1	–	0.1	–		
Other products	1.8	2.2	2.2	2.3	1.8	0.0	3.9	+77.3	3.3	+50.0	0.5	+150.0		
Other revenue	20.7	35.9	38.9	41.4	32.5	+57.0	34.9	(2.8)	50.9	+30.8	54.5	+31.6		
Revenue	312.2	267.4	257.9	273.8	236.9	(24.1)	315.9	+18.1	315.7	+22.4	302.1	+10.3		
Domestic	193.1	121.1	115.9	129.2	103.5	(46.4)	114.6	(5.4)	114.9	(0.9)	130.9	+1.3		
Overseas	119.1	146.3	141.9	144.6	133.5	+12.1	201.3	+37.6	200.8	+41.5	171.2	+18.4		

Core statements of revenue (YTD)

(Billions of yen)

	Actual				Actual								Forecast (Jan 30th announced)	
	FY2023				FY2024								FY2025	
	1-3	1-6	1-9	1-12	1-3	Change (%)	1-6	Change (%)	1-9	Change (%)	1-12	Change (%)	1-12	Change (%)
	YTD	YTD	YTD	YTD	YTD		YTD		YTD		YTD		YTD	
Sales	291.5	523.0	742.1	974.5	204.5	(29.8)	485.5	(7.2)	750.3	+1.1	997.9	+2.4	1,018.0	+2.0
Domestic	192.7	313.6	429.2	558.0	103.2	(46.4)	217.2	(30.7)	331.7	(22.7)	461.1	(17.4)	462.5	+0.3
Oncology	60.0	126.5	191.4	260.2	56.1	(6.5)	118.8	(6.1)	180.3	(5.8)	247.7	(4.8)	239.2	(3.4)
Tecentriq	15.1	31.6	47.9	65.5	14.5	(4.0)	31.1	(1.6)	47.4	(1.0)	65.4	(0.2)	62.0	(5.2)
Avastin	13.0	26.2	38.2	49.8	8.7	(33.1)	17.4	(33.6)	25.6	(33.0)	33.8	(32.1)	25.5	(24.6)
Polivy	7.2	15.9	25.5	35.5	7.4	+2.8	15.7	(1.3)	24.5	(3.9)	34.1	(3.9)	35.8	+5.0
Alecensa	6.6	14.5	22.0	30.3	6.6	0.0	14.9	+2.8	22.4	+1.8	31.0	+2.3	34.0	+9.7
Phesgo	–	–	–	0.7	3.2	–	8.6	–	15.0	–	23.5	34times	31.6	+34.5
Perjeta	7.5	16.1	24.6	33.6	6.1	(18.7)	11.3	(29.8)	15.7	(36.2)	20.0	(40.5)	11.9	(40.5)
Kadcyla	3.8	7.7	11.7	16.0	3.6	(5.3)	7.9	+2.6	12.2	+4.3	16.8	+5.0	16.6	(1.2)
Herceptin	1.3	2.5	3.6	4.8	0.7	(46.2)	1.4	(44.0)	1.9	(47.2)	2.4	(50.0)	1.4	(41.7)
Foundation Medicine	1.9	3.7	5.6	7.4	1.8	(5.3)	3.6	(2.7)	5.8	+3.6	7.6	+2.7	7.1	(6.6)
Other products	3.6	8.2	12.1	16.6	3.4	(5.6)	7.0	(14.6)	9.9	(18.2)	13.1	(21.1)	13.3	+1.5
Specialty	132.7	187.1	237.9	297.8	47.0	(64.6)	98.4	(47.4)	151.3	(36.4)	213.4	(28.3)	223.3	+4.6
Hemlibra	12.4	26.7	40.5	54.8	12.5	+0.8	27.4	+2.6	41.5	+2.5	59.0	+7.7	59.4	+0.7
Actemra	9.9	21.1	32.2	44.3	10.2	+3.0	22.4	+6.2	34.8	+8.1	48.0	+8.4	50.0	+4.2
Enspryng	4.7	10.9	16.9	23.9	5.8	+23.4	11.6	+6.4	17.8	+5.3	24.7	+3.3	26.0	+5.3
Vabysmo	3.0	6.7	10.8	15.3	4.0	+33.3	9.1	+35.8	14.7	+36.1	21.5	+40.5	23.5	+9.3
Evrysdi	3.0	6.6	10.3	14.5	3.4	+13.3	7.5	+13.6	11.3	+9.7	15.9	+9.7	15.9	0.0
Mircera	2.0	4.2	6.3	8.4	1.5	(25.0)	3.2	(23.8)	4.8	(23.8)	6.5	(22.6)	5.0	(23.1)
CellCept	1.6	3.5	5.2	7.0	1.5	(6.3)	3.1	(11.4)	4.7	(9.6)	6.8	(2.9)	5.8	(14.7)
Edirol	1.8	3.8	5.6	7.5	1.4	(22.2)	2.9	(23.7)	4.1	(26.8)	5.0	(33.3)	–	–
Piasky	–	–	–	–	–	–	0.4	–	1.3	–	2.6	–	4.4	+69.2
Ronapreve	81.2	81.2	81.2	81.2	–	–	–	–	–	–	–	–	–	–
Other products	13.1	22.4	29.0	40.9	6.7	(48.9)	10.7	(52.2)	16.2	(44.1)	23.5	(42.5)	33.2	+16.5
Tamiful	5.3	5.4	6.1	9.9	1.3	(75.5)	1.3	(75.9)	2.0	(67.2)	4.5	(54.5)	3.7	(11.1)
Overseas	98.8	209.4	312.9	416.5	101.3	+2.5	268.4	+28.2	418.7	+33.8	536.8	+28.9	555.5	+3.5
Hemlibra	46.0	103.9	171.8	212.3	57.8	+25.7	160.6	+54.6	253.5	+47.6	307.7	+44.9	324.2	+5.4
To Roche	45.2	102.3	169.4	208.8	56.9	+25.9	158.8	+55.2	250.6	+47.9	303.5	+45.4	318.6	+5.0
Actemra	31.8	65.1	86.5	127.5	23.4	(26.4)	61.6	(5.4)	93.6	+8.2	131.9	+3.5	127.6	(3.3)
To Roche	30.7	63.0	83.2	123.3	22.1	(28.0)	59.1	(6.2)	89.8	+7.9	126.8	+2.8	123.0	(3.0)
Alecensa	16.7	31.4	37.9	55.7	14.0	(16.2)	30.5	(2.9)	46.7	+23.2	62.8	+12.7	67.0	+6.7
To Roche	16.0	30.1	35.9	52.9	13.2	(17.5)	29.0	(3.7)	44.4	+23.7	59.7	+12.9	64.1	+7.4
Enspryng	0.7	1.1	4.3	4.2	2.1	+200.0	5.1	+363.6	8.8	+104.7	13.8	+228.6	12.6	(8.7)
To Roche	0.7	1.1	4.3	4.2	2.1	+200.0	4.9	+345.5	8.5	+97.7	13.5	+221.4	12.3	(8.9)
Sigmart	1.7	3.8	5.8	8.0	1.7	0.0	4.2	+10.5	6.1	+5.2	8.0	0.0	7.8	(2.5)
Neutrogin	1.9	3.9	6.0	8.1	2.1	+10.5	4.6	+17.9	6.7	+11.7	8.6	+6.2	6.5	(24.4)
Edirol	0.0	0.0	0.1	0.1	0.1	–	0.2	–	0.3	+200.0	0.5	+400.0	–	–
Other products	1.8	3.9	6.2	8.5	1.8	0.0	5.7	+46.2	9.0	+45.2	3.4	+580.0	9.8	+151.3
Other revenue	20.7	56.6	95.5	136.9	32.5	+57.0	67.3	+18.9	118.2	+23.8	172.7	+26.2	172.0	(0.4)
Revenue	312.2	579.7	837.6	1,111.4	236.9	(24.1)	552.9	(4.6)	868.5	+3.7	1,170.6	+5.3	1,190.0	+1.7
Domestic	193.1	314.2	430.1	559.3	103.5	(46.4)	218.1	(30.6)	333.0	(22.6)	463.9	(17.1)	463.5	(0.1)
Overseas	119.1	265.4	407.5	552.1	133.5	+12.1	334.8	+26.1	535.5	+31.4	706.7	+28.0	726.5	+2.8

The FY2025 forecast of “Edirol” is included in “Other products.”

Financial position

(Billions of yen)

	Actual				Actual										
	FY2023				FY2024										
	Mar. 31	Jun. 30	Sep. 30	Dec. 31	Mar. 31	vs. Mar. 31, 2023	vs. Dec. 31, 2023	Jun. 30	vs. Jun. 30, 2023	vs. Dec. 31, 2023	Sep. 30	vs. Sep. 30, 2023	vs. Dec. 31, 2023	Dec. 31	vs. Dec. 31, 2023
Trade accounts receivable	304.5	246.0	260.0	252.5	209.4	(95.1)	(43.1)	296.9	50.9	44.4	266.2	6.2	13.7	258.4	5.9
Inventories	278.9	266.4	277.5	273.5	276.7	(2.2)	3.2	265.7	(0.7)	(7.8)	273.2	(4.3)	(0.3)	240.1	(33.4)
Trade accounts payable	(112.5)	(42.9)	(53.9)	(54.2)	(40.4)	72.1	13.8	(40.4)	2.5	13.8	(44.7)	9.2	9.5	(16.1)	38.1
Other net working capital	(56.6)	(45.6)	(51.5)	(49.2)	(69.5)	(12.9)	(20.3)	(24.9)	20.7	24.3	(22.2)	29.3	27.0	(33.6)	15.6
Net working capital	414.2	423.9	432.1	422.6	376.1	(38.1)	(46.5)	497.3	73.4	74.7	472.5	40.4	49.9	448.7	26.1
Property, plant and equipment	389.1	395.6	406.0	409.9	416.3	27.2	6.4	420.3	24.7	10.4	426.3	20.3	16.4	433.1	23.2
Right-of-use assets	10.7	10.2	11.8	10.8	10.1	(0.6)	(0.7)	9.9	(0.3)	(0.9)	9.4	(2.4)	(1.4)	8.4	(2.4)
Intangible assets	19.7	20.7	20.0	19.9	19.6	(0.1)	(0.3)	20.4	(0.3)	0.5	20.8	0.8	0.9	17.9	(2.0)
Other long-term assets – net	42.1	42.5	37.0	37.8	40.6	(1.5)	2.8	42.1	(0.4)	4.3	42.5	5.5	4.7	39.5	1.7
Long-term net operating assets	461.5	468.9	474.8	478.3	486.6	25.1	8.3	492.6	23.7	14.3	499.0	24.2	20.7	498.9	20.6
Net operating assets	875.8	892.8	907.0	900.9	862.7	(13.1)	(38.2)	989.9	97.1	89.0	971.4	64.4	70.5	947.6	46.7
Debt	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Marketable securities	306.9	300.0	287.4	280.3	301.7	(5.2)	21.4	421.9	121.9	141.6	441.4	154.0	161.1	456.1	175.8
Cash and cash equivalents	247.7	365.0	331.3	458.7	462.9	215.2	4.2	393.8	28.8	(64.9)	404.0	72.7	(54.7)	540.2	81.5
Net cash	554.6	665.0	618.8	739.0	764.6	210.0	25.6	815.7	150.7	76.7	845.3	226.5	106.3	996.3	257.3
Other non-operating assets – net	6.5	(44.5)	9.3	(14.3)	14.8	8.3	29.1	(53.9)	(9.4)	(39.6)	(15.4)	(24.7)	(1.1)	(42.5)	(28.2)
Net non-operating assets	561.2	620.5	628.0	724.7	779.4	218.2	54.7	761.8	141.3	37.1	829.9	201.9	105.2	953.9	229.2
Total net assets	1,436.9	1,513.3	1,535.0	1,625.6	1,642.0	205.1	16.4	1,751.7	238.4	126.1	1,801.4	266.4	175.8	1,901.5	275.9
Total net assets															
Total assets	1,772.0	1,831.6	1,817.6	1,932.5	1,897.8	125.8	(34.7)	2,060.2	228.6	127.7	2,069.7	252.1	137.2	2,208.4	275.9
Total liabilities	(335.1)	(318.3)	(282.7)	(307.0)	(255.7)	79.4	51.3	(308.5)	9.8	(1.5)	(268.4)	14.3	38.6	(306.9)	0.1
Attributable to															
Chugai shareholders	1,436.9	1,513.3	1,535.0	1,625.6	1,642.0	205.1	16.4	1,751.7	238.4	126.1	1,801.4	266.4	175.8	1,901.5	275.9
Non-controlling interests	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Trade accounts receivable: trade receivable and notes receivable

Trade accounts payable: trade payable and notes payable

Other net working capital: accrued receivable (other receivable), accrued payable (other payable), accrued expenses (other current liabilities) etc.

Other long-term assets-net: long-term prepaid expenses, long-term provisions etc.

Other non-operating assets-net: deferred income tax assets, current income tax liabilities etc.

Net operating assets (NOA) and Net assets:

The consolidated balance sheet has been prepared in accordance with International Accounting Standards (IAS) No. 1, “Presentation of Financial Statements.” On the other hand, Net operating assets (NOA) and Net assets are a reconfiguration of the consolidated balance sheet as internal indicators and are identical to the indicators disclosed by Roche. Furthermore, no items from Net operating assets (NOA) and Net assets of IFRS have been excluded, as the Core results concept only applies to the income statement.

Net operating assets (NOA):

Net operating assets allow for an assessment of the Group’s operating performance of the business independently from financing and tax activities. Net operating assets are calculated as net working capital, long-term net operating assets that includes property, plant and equipment, right-of-use assets, intangible assets etc. minus provisions.

Cash flows

(Billions of yen)

	Actual FY2023				Actual FY2024			
	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12
	YTD	YTD	YTD	YTD	YTD	YTD	YTD	YTD
Operating profit – IFRS basis	98.3	210.9	317.6	439.2	99.9	258.2	418.6	542.0
Depreciation and impairment of property, plant and equipment	6.8	13.7	19.6	25.0	6.1	11.9	17.9	25.8
Depreciation and impairment of right-of-use assets	1.2	2.4	3.6	4.8	1.3	2.6	3.9	5.3
Amortization and impairment of intangible assets	5.4	6.3	7.1	7.6	0.6	1.2	2.8	6.4
Other cash adjustment on operating profit	15.2	6.0	9.9	14.9	0.3	1.2	1.2	5.3
Operating profit, net of operating cash adjustments	126.8	239.3	357.7	491.5	108.2	275.1	444.5	584.8
(Increase) decrease in trade accounts receivable	132.0	190.7	176.8	184.3	43.6	(43.4)	(13.6)	(5.3)
(Increase) decrease in inventories	13.1	26.8	13.3	16.7	(0.0)	11.2	2.7	34.0
Increase (decrease) in trade accounts payable	(31.6)	(101.6)	(90.8)	(90.3)	(14.2)	(14.8)	(9.5)	(38.7)
Change in other net working capital etc.	10.7	13.6	18.6	20.0	14.7	(19.9)	(17.6)	(18.8)
Total (increase) decrease in net working capital etc.	124.2	129.6	117.9	130.6	44.1	(67.0)	(38.0)	(28.8)
Investment in property, plant and equipment	(27.2)	(45.2)	(54.1)	(71.9)	(12.4)	(32.9)	(50.2)	(50.4)
Lease liabilities paid	(2.0)	(3.9)	(5.9)	(7.9)	(2.0)	(4.0)	(6.1)	(8.1)
Investment in intangible assets	–	(1.4)	(1.9)	(2.3)	(0.1)	(1.7)	(2.9)	(4.0)
Operating free cash flows	221.8	318.3	413.6	540.1	137.9	169.5	347.4	493.4
as % of Revenue	71.0%	54.9%	49.4%	48.6%	58.2%	30.7%	40.0%	42.1%
Treasury activities (interest income/expenses, foreign exchange gains/losses etc.)	(11.0)	(0.7)	4.1	(0.2)	(9.7)	5.2	(8.8)	(6.2)
Tax paid	(95.6)	(96.0)	(175.8)	(176.1)	(41.0)	(40.0)	(100.4)	(100.5)
Free cash flows	115.2	221.6	242.0	363.8	87.2	134.7	238.2	386.8
Dividends paid	(65.4)	(65.8)	(131.2)	(131.6)	(65.0)	(65.5)	(133.0)	(133.2)
Transaction in own equity instruments	0.1	0.2	0.2	0.2	0.1	0.1	0.1	0.2
Net effect of currency translation on net cash	1.5	6.0	4.7	3.5	3.3	7.4	1.0	3.7
Net change in net cash	51.5	161.9	115.7	235.9	25.6	76.7	106.3	257.3

Other cash adjustment on operating profit: Adjustments for all non-cash income and expense items other than amortization expenses and impairment included in operating profit (such as loss on inventory differences, reserve for doubtful accounts, stock option expenses, loss on asset retirement, and increase/decrease in reserves) as well as all non-operating income and expense cash flows relating to net operating assets (NOA) including proceeds from the sales of assets and reserve payments.

Operating free cash flow (Operating FCF): Pretax cash flow after adjusting changes in working capital and operating investments in assets (tangible and intangible) to “operating profit, net of operating cash adjustments,” which shows the company’s cash generation ability from operating activities.

Free cash flow (FCF): the ability to generate net cash from a management perspective after deducting tax, dividends, and other payments from operating FCF.

Net change in net cash: dividends paid, increases and decreases in marketable securities and interest-bearing debt, changes in equity are included.

The concepts of operating profit, operating FCF and Net operating assets (NOA) presented in the previous page are mutually consistent.

Free cash flow (FCF):

The consolidated statement of cash flows has been prepared in accordance with International Accounting Standard (IAS) No. 7, “Statement of Cash Flows.” FCF is a reconfiguration of the consolidated statement of cash flows as internal indicators and is identical to the indicators disclosed by Roche. Furthermore, no items from FCF have been excluded, as the Core results concept only applies to the income statement.

Key Performance Indicators

		Actual				Actual				Forecast (Jan 30th announced)
		2023				2024				2025
		1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	1-12
	Units	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Dec. 31
Total indicator										
Core return on invested capital (Core ROIC)	%	8.2	17.8	25.9	34.6	8.6	20.0	32.3	42.9	
Return on invested capital (ROIC)	%	7.7	16.3	24.2	33.8	8.4	19.6	31.7	41.8	
Ratio of profit to total assets (ROA)	%	4.0	8.5	12.7	17.1	3.9	9.3	14.8	18.7	
Ratio of equity attributable to Chugai shareholders	%	81.1	82.6	84.4	84.1	86.5	85.0	87.0	86.1	
Ratio of equity attributable to Chugai shareholders (stock price base)	%	303.6	367.0	418.5	454.8	500.6	456.5	551.1	521.5	
Price book value ratio (PBR)	times	3.7	4.4	5.0	5.4	5.8	5.4	6.3	6.1	
Ratio of net income to equity attributable to Chugai shareholders (ROE)	%	5.1	10.7	15.8	21.3	4.6	11.0	17.3	22.0	
Margin indicator (Core)										
ROS	%	33.8	40.0	40.7	40.6	43.1	47.5	49.1	47.5	47.9
COS ratio (vs. Prod. sales)	%	51.8	46.3	43.2	42.3	35.5	33.0	32.5	33.9	33.5
R&D cost ratio	%	11.6	13.2	14.5	14.6	17.4	15.2	14.7	15.1	15.0
Selling, general and administration cost ratio	%	6.7	7.8	8.5	9.2	9.0	8.4	8.3	8.7	8.5
Turnover indicator										
Total asset turnover	%	17.1	31.3	45.4	58.5	12.4	27.7	43.4	56.5	
Working capital turnover	%	33.3	61.3	87.9	117.0	26.9	58.5	92.8	126.7	
Inventory turnover	Months	5.4	6.6	7.8	7.9	11.4	9.9	10.0	8.5	
Receivables turnover	Months	3.1	2.8	3.2	3.1	3.1	3.7	3.2	3.1	
Payables turnover	Months	2.2	1.1	1.5	1.6	1.7	1.5	1.6	0.6	
Fixed asset turnover	%	75.1	138.3	197.2	260.8	53.5	124.1	193.6	260.1	
PP&E turnover	%	81.7	150.4	214.4	283.1	57.4	133.2	207.7	277.7	
Intangible assets turnover	%	1,392.9	2,529.6	3,712.4	4,939.3	1,202.2	2,749.9	4,269.7	6,205.5	
Dividend / per stock indicator										
Dividends per share (Half year)	Yen	40				41				125
Dividends per share (Year end)	Yen	40				57				125
Dividends per share (Full year)	Yen	80				98				250
Core earnings per share (diluted)	Yen	47.66	104.19	152.11	202.71	46.16	115.15	183.09	241.31	250.00
Core payout ratio (%)	%	39.5				40.6				100.0
Equity per share attributable to Chugai shareholders (BPS)	Yen	873.44	919.80	932.97	988.01	997.97	1,064.55	1,094.71	1,155.56	
Ratio of dividends to equity attributable to Chugai shareholders (DOE)	%	8.6				9.1				
Cashflow indicator										
Cash conversion cycle(CCC)	Months	6.4	8.3	9.4	9.5	12.8	12.1	11.6	11.0	
Net cash turnover period	Months	5.3	6.9	6.6	8.0	9.7	8.9	8.8	10.2	
Number of employees										
Investment on property, plant and equipment	Billions of yen	21.1	37.5	53.8	68.3	15.5	25.1	37.7	52.8	75.0
Depreciation	Billions of yen	6.8	12.5	18.3	24.3	6.1	11.9	17.8	24.2	24.0
Investment on intangible assets	Billions of yen	—	1.8	1.9	2.4	0.3	1.6	3.8	4.4	
Amortization	Billions of yen	0.8	1.4	2.0	2.6	0.6	1.1	1.6	2.2	

Core ROIC: Core net operating profit after taxes / Net operating assets (Core ROIC is calculated by using Core Income taxes)

ROIC: Net operating profit after taxes / Net operating assets (Net operating profit after taxes = Operating profit – income taxes)

ROA: Net income / total assets, ROE: Net income attributable for Chugai shareholders / Equity attributable to Chugai shareholders

Total asset turnover: Revenues / Total asset, CCC: [Trade accounts receivable/Sales + (Inventories – Trade accounts payable)/Cost of sales]* passed months

Net cash turnover period: Net cash/Revenue * passed months

Core ROIC, ROIC, ROA, ROE, total asset turnover, working capital turnover, fixed asset turnover, PP&E turnover, and intangible assets turnover are not annualized

The Adjusted figures are used for calculating average NOA for Core ROIC and ROIC

The dividend forecast for the full year is an annual total of 250 yen per share, which includes an ordinary dividend of 100 yen (50 yen interim, 50 yen year–end)

and a 100th anniversary dividend of 150 yen (75 yen interim, 75 yen year–end).

■ Oncology
 ■ Immunology
 ■ Neuroscience
 ■ Hematology
 ■ Ophthalmology
 ■ Other Diseases

Development Pipeline [Main table] (as of January 30, 2025)

Development code Origin		Generic name Product name	Indication # Additional indication (Combination drug)	Country/region	Projected submission	Mode of Action Modality (Dosage form)	Partner
Filed							
	RG7446 Roche	atezolizumab Tecentriq	Alveolar soft part of sarcoma #	Japan	March 2024	Engineered anti-PD-L1 monoclonal antibody Antibody (IV)	—
			Relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type #	Japan	October 2024		
	RG6356/SRP-9001 Sarepta	delandistrogene moxeparvovec -	Duchenne muscular dystrophy (DMD)	Japan	August 2024	Microdystrophin gene therapy Gene therapy (IV)	Sarepta*
	RG7716 Roche	faricimab Vabysmo	Angioid streaks #	Japan	September 2024	Anti-VEGF/Anti-Ang-2 bispecific antibody Antibody (vitreous injection)	—
Phase III							
	AF802/RG7853 in-house	alectinib Alecensa	Maintenance treatment of NSCLC (stage III) after chemoradiotherapy #	Global	-	ALK inhibitor Small molecule (oral)	Roche
	RG7446 Roche	atezolizumab Tecentriq	NSCLC (perioperative) #	Japan	2026	Engineered anti-PD-L1 monoclonal antibody Antibody (IV)	Roche
			Muscle-invasive bladder cancer (adjuvant) #	Japan	2025		Roche
			HCC (intermediate stage) # (Avastin) #	Japan	2025		Roche
			HCC (2nd Line) # (lenvatinib or sorafenib)	Japan	-		Roche
	RG435 Roche	bevacizumab Avastin	Small cell lung cancer (SCLC) (1st Line) # (Tecentriq)	Japan/ China	2026	Anti-VEGF (Vascular Endothelial Growth Factor) humanized monoclonal antibody Antibody (IV)	Roche (China)

■ Oncology
 ■ Immunology
 ■ Neuroscience
 ■ Hematology
 ■ Ophthalmology
 ■ Other Diseases

Development code Origin	Generic name Product name	Indication # Additional indication (Combination drug)	Country/region	Projected submission	Mode of Action Modality (Dosage form)	Partner
■ Roche	tiragolumab -	NSCLC (stage III) (Tecentriq) #	Japan	2025	Anti-TIGIT human monoclonal antibody Antibody (IV)	Roche
		Esophageal cancer (Tecentriq) #	Japan	2025		Roche
		HCC (1st line) (Tecentriq/Avastin)	Japan	2027 and beyond		Roche
■ Roche	giredestrant -	Breast cancer (adjuvant)	Japan	2027 and beyond	SERD (Selective Estrogen Receptor Degradar) Small molecule (Oral)	Roche
		Breast cancer (1st Line) (palbociclib + letrozole)	Japan	2026		Roche
		Breast cancer (1st Line-3rd Line) (everolimus)	Japan	-		Roche
■ Roche	mosunetuzumab Lunsumio	Follicular lymphoma (2nd Line) # (lenalidomide)	Japan	2026	Anti-CD20/CD3 bispecific antibody Antibody (IV)	Roche
		Relapsed or refractory aggressive B-cell non- Hodgkin's lymphoma # (Polivy) #	Japan	2025	Anti-CD20/CD3 bispecific antibody Antibody (SC)	Roche
		Previously untreated follicular lymphoma #	Japan	2027 and beyond	Anti-CD20/CD3 bispecific antibody Antibody (IV)	Roche
■ Roche	glofitamab	Previously untreated large B- cell lymphoma (Polivy)	Japan	2027 and beyond	Anti-CD20/CD3 bispecific antibody Antibody (IV)	Roche
■ Roche	divarasib -	NSCLC (2nd Line)	Japan	2027 and beyond	KRAS G12C inhibitor Small molecule (Oral)	Roche
■ GlycArt Biotechnology	obinutuzumab Gazyva	Lupus nephritis #	Japan	2026	Glycoengineered type II anti- CD20 monoclonal Antibody Antibody (IV)	Nippon shinyaku
		Pediatric nephrotic syndrome #	Japan	2026		Nippon shinyaku
		Extra renal lupus #	Japan	2027 and beyond		Nippon shinyaku

■ Oncology
 ■ Immunology
 ■ Neuroscience
 ■ Hematology
 ■ Ophthalmology
 ■ Other Diseases

■ Oncology
 ■ Immunology
 ■ Neuroscience
 ■ Hematology
 ■ Ophthalmology
 ■ Other Diseases

Development code Origin	Generic name Product name	Indication # Additional indication (Combination drug)	Country/region	Projected submission	Mode of Action Modality (Dosage form)	Partner
■ GYM329/ RG6237 in-house	- -	Facioscapulohumeral muscular dystrophy (FSHD)	Global	2027 and beyond	Anti-latent myostatin sweeping antibody Antibody (SC)	Roche
■ RG6042 Ionis Pharmaceuticals	tominersen -	Huntington's disease	Japan	-	Antisense oligonucleotide targeting <i>HTT</i> mRNA Nucleic acid (IV)	Roche
■ SKY59/RG6107 in-house	crovalimab PiaSky	Sickle cell disease (SCD)	US · EU	2027 and beyond	Anti-C5 recycling antibody Antibody (SC)	Roche
■ AMY109 in-house	- -	Endometriosis	Global	-	Anti-IL-8 recycling antibody Antibody (SC)	-
Phase I/II						
■ RG6102 MorphoSys	trontinemab —	Alzheimer's disease	Japan	-	Anti-amyloid beta/TfR1 fusion protein Antibody (IV)	Roche
■ NXT007/ RG6512 in-house	- -	Hemophilia A	Global	2027 and beyond	Anti-coagulation factor IXa/X bispecific antibody Antibody (SC)	Roche
■ RG6321 Roche	ranibizumab (Port delivery system) -	Neovascular age-related macular degeneration	Japan	2026	Humanized anti-VEGF monoclonal antibody Fragment Fab	-
		Diabetic macular edema	Japan	2026	Antibody (injection via implant)	-
■ RG6615 Alnylam Pharmaceuticals	zilebesiran	Hypertension	Japan	-	RNAi therapeutic targeting angiotensinogen (AGT) RNAi (SC)	Alnylam Pharma ceuticals
Phase I						
■ LUNA18 in-house	paluratide -	Solid tumors	Global	-	RAS inhibitor Mid-size molecule (Oral)	-

■ Oncology
 ■ Immunology
 ■ Neuroscience
 ■ Hematology
 ■ Ophthalmology
 ■ Other Diseases

Development code Origin	Generic name Product name	Indication # Additional indication (Combination drug)	Country/region	Projected submission	Mode of Action Modality (Dosage form)	Partner
■ GC33 in-house	codrituzumab -	HCC	Global	-	Anti-Glypican-3 humanized monoclonal antibody Antibody (IV)	-
■ STA551 in-house	- -	Solid tumors	Global	-	Anti-CD137 agonistic Switch antibody Antibody (IV)	-
■ SOF10/RG6440 in-house	- -	Solid tumors	Global	-	Anti-latent TGF-β1 monoclonal antibody Antibody (IV)	Roche
■ ALPS12/RG6524 in-house	- -	Solid tumors	Global	-	Anti-DLL3/CD3/CD137 trispecific antibody Antibody (IV)	Roche
■ SAIL66 in-house	- -	CLDN6 positive solid tumors	Global	-	Anti-CLDN6/CD3/CD137 trispecific antibody Antibody (IV)	-
■ ROSE12 in-house	- -	Solid tumors	Global	-	Anti-CTLA-4 Switch antibody Antibody (IV)	-
■ RG7421 Exelixis	cobimetinib -	Solid tumors	Japan	-	MEK inhibitor Small molecule (Oral)	-
■ RG6026 Roche	glofitamab -	Hematologic tumors	Japan	-	Anti-CD20/CD3 bispecific antibody Antibody (IV)	-
■ RG6160 Roche	cevostamab -	Relapsed or refractory multiple myeloma	Japan	-	Anti-FcRH5/CD3 bispecific antibody Antibody (IV)	-
■ DONQ52 in-house	- -	Celiac disease	Global	-	Anti-HLA-DQ2.5/gluten peptides multispecific antibody Antibody (SC)	-
■ RAY121 in-house	- -	Autoimmune disease	Global	-	Anti-C1s recycling antibody Antibody (-)	-
■ RG7935 Prothena	prasinezumab -	Parkinson's disease	Japan	-	Anti-α-synuclein monoclonal antibody Antibody (IV)	-

■ Oncology
 ■ Immunology
 ■ Neuroscience
 ■ Hematology
 ■ Ophthalmology
 ■ Other Diseases

Development code Origin		Generic name Product name	Indication # Additional indication (Combination drug)	Country/region	Projected submission	Mode of Action Modality (Dosage form)	Partner
	REVN24	-	Acute diseases	Global	-	-	-
	in-house	-				Small molecule (IV)	
	GYM329/RG6237	-	Obesity	Global	-	Anti-latent myostatin sweeping antibody	Roche
	In-house	-				Antibody (SC)	
	BRY10	-	Chronic diseases	Global	—	-	-
	In-house	-				Antibody (SC)	
Development Discontinued							
Development code Origin		Generic name Product name	Indication # Additional indication (Combination drug)	Country/region	Development stage	Mode of Action Modality (Dosage form)	Partner
	RG7446	atezolizumab	Early breast cancer (perioperative) #	Japan	Phase III	Engineered anti-PD-L1 monoclonal antibody Antibody (IV)	Roche
	Roche	Tecentriq	Prostate cancer (2nd Line) # (cabozantinib)				Takeda, Exelixis
	RG6058	tiragolumab	NSCLC (1st Line) (Tecentriq)	Japan	Phase III	Anti-TIGIT human monoclonal antibody Antibody (IV)	Roche
	ERY974	-	Solid tumors	Global	Phase I	Anti-Glypican-3/CD3 bispecific antibody Antibody (IV)	-
	RG6194	runimotamab	Solid tumors	Japan	Phase I	Anti-HER2/CD3 bispecific antibody Antibody (IV)	Roche

In principle, completion of first dose is regarded as pipeline entry into each phase of clinical studies.

* Sarepta manages the global study including Japan

Changes from the last announcement on October 25, 2024

Oncology

- RG7828 Filed (Follicular lymphoma (3rd Line)) (Japan) → Approved
- RG7446 Filed (Relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type)
- RG7828 Phase III (Previously untreated follicular lymphoma: development started)
- RG7446 Phase III (Early breast cancer (perioperative): development discontinued)
- RG7446 Phase III (Prostate cancer (2nd Line) (combination with cabozantinib): development discontinued)
- RG6058 Phase III (NSCLC (1st Line) (combination with RG7446): development discontinued)
- ERY974 Phase I (Solid tumors: development discontinued)
- RG6194 Phase I (Solid tumors: development discontinued)

R&D Activities

For the changes during the FY2024 (January 1 –December 31), please refer to page 5 of “CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited)(for the fiscal year 2024).”

Changes from January 1, 2025 to January 30, 2025 are as follows:

Oncology

- We decided to discontinue the domestic development of an antineoplastic agent/humanized anti-PD-L1 monoclonal antibody RG7446 (Product name: Tecentriq) for prostate cancer (2nd Line) (combination with cabozantinib) in consideration of the results of global Phase III study CONTACT-02. We also decided to discontinue the development for early breast cancer (perioperative) in consideration of the results of prior clinical studies.
- We decided to discontinue the development of an anti-TIGIT human monoclonal antibody RG6058 for non-small cell lung cancer (1st Line) in combination with RG7446, considering the results of global Phase III study SKYSCRAPER-01.
- We decided to discontinue the development of an anti-HER2/CD3 bispecific antibody RG6194 for solid tumors in consideration of business strategy.

Development Pipeline [Attached table] (Major Chugai originated developments licensed out to 3rd parties excluding Roche)

Development code licensee/In-house	Generic name Product name	Indication # Additional Indication (combination)	Stage Country/region	Mode of Action Modality (Dosage form)	Licensee (Granted rights)
VS-6766/CKI27	avutometinib —	Recurrent LGSOC (defactinib)	Phase III/Filed* Global/U.S.	RAF/MEK clamp Small molecule (Oral)	Verastem Oncology (exclusive global license for the manufacturing, development and marketing)
			Phase II Japan		
		NSCLC (sotorasib±defactinib)	Phase I/II Global, U.S.		
		mPDAC (1st line) (defactinib+chemotherapy)	Phase I/II U.S.		
- /CIM331	nemolizumab NEMLUVIO®	Atopic dermatitis	Filed EU	Anti-IL-31 receptor A humanized monoclonal antibody Antibody (SC)	Galderma (exclusive global license for the development and marketing excluding Japan and Taiwan)
		Prurigo nodularis	Filed EU		
LY3502970/OWL833	orforglipron —	Type 2 diabetes	Phase III Global	Oral non-peptidic GLP-1 receptor agonist Small molecule (Oral)	Eli Lilly and Company (worldwide development and commercialization rights)
		Obesity	Phase III Global		
AP306/EOS789	—	Hyperphosphatemia	Phase II China	Oral inhibitor of phosphate transporters Small molecule (Oral)	Alebund (exclusive global license for the manufacturing, development and marketing)

* New Drug Application (NDA) under the accelerated approval pathway was accepted. The NDA has been granted Priority Review with a Prescription Drug User Fee Act (PDUFA) action date of June 30, 2025.

Progress made in R&D activities of major Chugai originated developments licensed out to 3rd party excluding Roche during the period from January 1, 2024 to January 30, 2025 was as follows.

- In Japan, Maruho obtained regulatory approval for the anti-IL-31 receptor A humanized monoclonal antibody nemolizumab (Product name in Japan: Mitchga) for the treatment for the following diseases in patients only when existing treatment is insufficiently effective: pruritus associated with atopic dermatitis (children

aged ≥ 6 and < 13 years), prurigo nodularis (adults and children aged ≥ 13 years) in March, and launched in June 2024. Overseas, the applications for approval of nemolizumab for the treatment of prurigo nodularis and atopic dermatitis were accepted in the U.S., and Europe in February 2024 and in the countries whose regulatory authorities are members of the Access Consortium in May 2024, respectively. As a result, in the U.S., Galderma obtained regulatory approval for prurigo nodularis in August in the same year and for moderate to severe atopic dermatitis in December in the same year (Product name in the U.S.: NEMLUVIO). In Europe, in December in the same year, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion and recommended approval for moderate-to-severe atopic dermatitis and prurigo nodularis. And Galderma decided to deprioritize the chronic kidney disease associated pruritus (CKD-aP) program given the existing CKD-aP treatment landscape.

- The RAF/MEK clamp CKI27 received Fast Track designation for KRAS G12C mutated non-small cell lung cancer in combination with the FAK inhibitor defactinib and sotorasib in April 2024. Additionally, a rolling submission was initiated in the U.S., for recurrent KRAS mutant low-grade serous ovarian cancer in patients who have received at least one prior line of systemic therapy in combination with the FAK inhibitor defactinib in May 2024. This rolling submission was completed in October in the same year, and in December, a New Drug Application (NDA) under the accelerated approval pathway was accepted by the U.S. Food and Drug Administration (FDA) in the same year.

- The inhibitor of phosphate transporters EOS789 received Breakthrough Therapy designation for the treatment of hyperphosphatemia in patients with chronic kidney disease in China in June 2024.

Response to Requests from the MHLW Review Committee on Unapproved Drugs and Indications with High Medical Needs (As of January 30, 2025)

Development Request	Product	Indication	Development Status
Fourth development request	Xeloda*	Neuroendocrine tumor	Submitted company opinion and waiting for evaluation by committee
	Avastin	Cerebral edema induced by radiation necrosis	Submitted company opinion and waiting for evaluation by committee
	CellCept	Remission maintenance therapy following rituximab therapy for refractory nephrotic syndrome (frequently relapsing or steroid-dependent nephrotic syndrome)	Submitted company opinion and waiting for evaluation by committee

*Transferred the marketing authorization holder to CHEPLAPHARM K.K. as of February 1, 2024

Major Clinical Trials

Project	Expected indication	Study design	Study name	Stage	CT information
Oncology					

Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Statements for the FY2024 (IFRS) 20

Project	Expected indication	Study design	Study name	Stage	CT information
RG7446 (Tecentriq)	NSCLC (periadjuvant)	Chemo ± Tecentriq	IMpower030	Phase III	NCT03456063
	SCLC [1st line]	Tecentriq + chemo ± Avastin	BEAT-SC	Phase III	JapicCTI-195034 (Japanese only)
	Muscle-invasive bladder cancer (adjuvant)	Tecentriq vs. placebo	IMvigor011	Phase III	NCT04660344
	HCC (intermediate stage)	Tecentriq + Avastin + TACE vs. TACE	TALENTACE	Phase III	NCT04803994
	HCC [2nd line]	Tecentriq + lenvatinib or sorafenib vs. lenvatinib or sorafenib	IMbrave251	Phase III	NCT04770896
RG6058 (tiragolumab)	NSCLC [stage III]	Tecentriq + RG6058 vs. durvalumab	SKYSCRAPER-03	Phase III	NCT04513925
	Esophageal cancer	Tecentriq + RG6058 vs. Tecentriq vs. placebo	SKYSCRAPER-07	Phase III	NCT04543617
	HCC (1st line)	Tecentriq + Avastin ± RG6058	IMbrave152/SKYSC RAPER-14	Phase III	NCT05904886
AF802/RG7853 (Alecensa)	Maintenance treatment of NSCLC (stage III) after chemoradiotherapy	ALK fusion-positive: Alecensa vs. durvalumab	HORIZON01	Phase III	NCT05170204
RG6171/SERD (giredestrant)	Breast cancer (adjuvant)	HR positive: RG6171 vs. endocrine therapy	lidERA	Phase III	NCT04961996
	Breast cancer [1st line]	HR positive: RG6171 + palbociclib ± Letrozole	persevERA	Phase III	NCT04546009
	Breast cancer [1st line-3rd line]	HR positive: RG6171 + everolimus vs. endocrine therapy+ everolimus	evERA	Phase III	NCT05306340
RG7828 (mosunetuzumab)	Follicular lymphoma [2nd line]	RG7828 + lenalidomide vs Rituxan + lenalidomide	CELESTIMO	Phase III	NCT04712097
	Relapsed or refractory aggressive B- cell non-Hodgkin's lymphoma	RG7828 + Polivy vs Rituxan + chemotherapy	SUNMO	Phase III	NCT05171647
	Previously untreated follicular lymphoma	RG7828+ lenalidomide vs. Rituxan + chemotherapy	-	Phase III (domestic)	JRCT2011240017 (Japanese only)
RG6026 (glofitamab)	Previously untreated large B-cell lymphoma	RG6026 + Polivy + Rituxan + chemotherapy vs Polivy + Rituxan + chemotherapy	SKYGLO	Phase III	NCT06047080
RG6330 (divarasib)	NSCLC [2nd line]	divarasib vs. sotorasib or adagrasib	Krascendo 1	Phase III	NCT06497556
Immunology					
RG7159 (Gazyva)	Lupus nephritis	standard treatment ± Gazyva	-	Phase III (domestic)	JRCT2011210059 (Japanese only)
	Pediatric nephrotic syndrome	Gazyva vs. MMF	INShore	Phase III	NCT05627557

Project	Expected indication	Study design	Study name	Stage	CT information
	Extra renal lupus	Gazyva vs. Placebo	-	Phase III (domestic)	jRCT2071230031 (Japanese only)
RG6299	IgA nephropathy	RG6299 vs. Placebo	IMAGINATION	Phase III	NCT05797610
Neuroscience					
SA237/RG6168 (Enspryng)	Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)	Enspryng vs. Placebo	METEOROID	Phase III	NCT05271409
	Autoimmune encephalitis (AIE)	Enspryng vs. Placebo	CIELO	Phase III	NCT05503264
RG6356/SRP-9001 (delandistrogene moxeparvovec)	Duchenne muscular dystrophy (DMD) (non-ambulatory)	RG6356 vs. Placebo	ENVISION	Phase III	NCT05881408
GYM329/RG6237	Spinal muscular atrophy (SMA)	GYM329 ± Evrysdi	MANATEE	Phase II/III	NCT05115110
	Facioscapulohumeral muscular dystrophy (FSHD)	GYM329 ± Placebo	MANOEUVRE	Phase II	NCT05548556
Hematology					
SKY59/RG6107 (PiaSky)	Atypical hemolytic uremic syndrome (aHUS)	PiaSky (single arm)	COMMUTE-a	Phase III	NCT04861259
			COMMUTE-p	Phase III	NCT04958265
	Sickle cell disease (SCD)	PiaSky vs. Placebo	CROSSWALK-c	Phase IIa	NCT05075824
Ophthalmology					
RG6179	Noninfectious uveitic macular edema	RG6179 (single arm)	Sandcat	Phase III	NCT05642325
SA237/RG6168 (Enspryng)	Thyroid eye disease (TED)	Enspryng vs. Placebo	SatraGo 1/ SatraGo 2	Phase III	NCT05987423 NCT06106828
RG6321 (ranibizumab (Port delivery system))	Neovascular age-related macular degeneration / Diabetic macular edema	RG6321 (single arm)	-	Phase I/II (domestic)	jRCT2071210073 (Japanese only)

Clinical Trials of In-House Developed Projects

*Excluding in-house developed projects listed in Major Clinical Trials of the development pipeline. Only clinical trials led by Chugai or Roche are listed.

Project	Expected indication	Stage	Enrollment as of December 31, 2024	Study start	CT information
Oncology					
LUNA18	Solid tumors	Phase I	195	October, 2021	NCT05012618

Project	Expected indication	Stage	Enrollment as of December 31, 2024	Study start	CT information
GC33	HCC	Phase I	27	November, 2008	NCT00746317
		Phase I	42	October, 2009	NCT00976170
		Phase I (domestic)	18	October, 2010	jRCT2080221218 (Japanese only)
		Phase II	185	May, 2012	NCT01507168
		Phase I	27	August, 2016	jRCT2080223270 (Japanese only)
STA551	Solid tumors	Phase Ia/Ib	233	March, 2020	2023-508764-30-00
SOF10/RG6440	Solid tumors	Phase I (domestic)	66	June, 2021	jRCT2031200407 (Japanese only)
		Phase Ib	102	October, 2023	NCT05867121
ALPS12/RG6524	Solid tumors	Phase I	168	January, 2023	NCT05619744
SAIL66	CLDN6-positive solid tumors	Phase I	231	April, 2023	NCT05735366
ROSE12	Solid tumors	Phase Ia/Ib	219	June, 2023	NCT05907980
Immunology					
DONQ52	Celiac disease	Phase Ia/Ib	56	September, 2022	NCT05425446
		Phase Ic	56	July, 2024	ACTRN12624000316505
RAY121	Autoimmune disease	Phase I (domestic) (only healthy adults)	40	October, 2022	jRCT2071220036 (Japanese only)
		Phase Ib	144	August, 2024	jRCT2041240035 (Japanese only)
Hematology					
NXT007/RG6512	Hemophilia A	Phase I/II	106	August, 2019	jRCT2080224835 (Japanese only)
		Phase I (domestic) (only healthy adults)	30	May, 2022	jRCT2031220050 (Japanese only)
		Phase I/II	40	October, 2023	NCT05987449
Other diseases					
AMY109	Endometriosis	Phase I (domestic)	100	October, 2018	jRCT2080223785 (Japanese only)
		Phase II	120	January, 2024	ISCTRN15654320

Project	Expected indication	Stage	Enrollment as of December 31, 2024	Study start	CT information
REVN24	Acute diseases	Phase I (domestic) (only healthy adults)	210	October, 2023	jRCT2071230074 (Japanese only)
BRY10	Chronic diseases	Phase I (domestic) (only healthy adults)	72	September, 2024	jRCT2051240123 (Japanese only)

* The number of enrollments is listed based on public information and generally refers to estimations or actual results.

FoundationOne CDx Cancer Genomic Profile: companion diagnostic indications (as of January 30, 2025)

Alterations	Cancer type	Relevant drugs
Activating <i>EGFR</i> alterations	NSCLC	afatinib maleate, erlotinib hydrochloride, gefitinib, osimertinib mesilate, dacomitinib hydrate
<i>EGFR</i> exon 20 T790M alteration		osimertinib mesilate
<i>ALK</i> fusion genes		alectinib hydrochloride, crizotinib, ceritinib, brigatinib
<i>ROS1</i> fusion genes		entrectinib
<i>MET</i> exon 14 skipping alterations		capmatinib hydrochloride hydrate
<i>BRAF</i> V600E and V600K alterations	Malignant melanoma	dabrafenib mesilate, trametinib dimethyl sulfoxide, vemurafenib, encorafenib, binimetinib
<i>ERBB2</i> copy number alterations (HER2 gene amplification positive)	Breast cancer	trastuzumab (genetical recombination)
<i>AKT1</i> alterations		capivasertib
<i>PIK3CA</i> alterations		
<i>PTEN</i> alterations		
<i>KRAS/NRAS</i> wildtype	Colorectal cancer	cetuximab (genetical recombination), panitumumab (genetical recombination)
Microsatellite instability-high		nivolumab (genetical recombination)
Microsatellite instability-high	Solid tumors	pembrolizumab (genetical recombination)
Tumor mutational burden-high		pembrolizumab (genetical recombination)
<i>NTRK1/2/3</i> fusion genes		entrectinib, larotrectinib sulfate
<i>RET</i> fusion genes		selpercatinib
<i>BRCA1/2</i> alterations	Ovarian cancer	olaparib
<i>BRCA1/2</i> alterations	Prostate cancer	olaparib, talazoparib tosilate
<i>FGFR2</i> fusion genes	Biliary tract cancer	pemigatinib

FoundationOne Liquid CDx Cancer Genomic Profile: companion diagnostic indications (as of January 30, 2025)

Alterations	Cancer type	Relevant drugs
Activating <i>EGFR</i> alterations	NSCLC	afatinib maleate, erlotinib hydrochloride, gefitinib, osimertinib mesilate
<i>EGFR</i> exon 20 T790M alteration		osimertinib mesilate
<i>ALK</i> fusion genes		alectinib hydrochloride, crizotinib, ceritinib
<i>ROS1</i> fusion genes		entrectinib
<i>MET</i> exon 14 skipping alterations		capmatinib hydrochloride hydrate
<i>NTRK1/2/3</i> fusion genes	Solid tumors	entrectinib
<i>BRCA1/2</i> alterations	Prostate cancer	olaparib